Sarah Bertino

Company: TScan Therapeutics

Job title: Senior Director, Business Development

Seminars:

Identifying Novel Autoantigen Targets and Clinically De-Risked TCRs to Deploy in Tolerizing Therapies 4:00 pm

TargetScan platform identifies the natural target of any T cell receptor (TCR) in an unbiased, genome-wide manner, enabling discovery of disease-mediating autoantigens for autoimmune diseases ReceptorScan platform enables identification of highly active TCRs for a desired target and HLA type, and TCRs can also be clinically de-risked by characterizing potential off-targets using TargetScan technology These…Read more

day: Day One | Track A | Afternoon